Immediately after the US Food and Drug Administration released its briefing document for the forthcoming advisory committee review of Pfizer Inc./BioNTech SE’s COVID-19 vaccine candidate, a panel of former FDA commissioners gave their positive take on the agency’s analysis.
Speaking at the Milken Institute’s 8 December Future of Health Summit, Mark McClellan, director of the Duke-Margolis Center for Health...





